GIMBHI’s daily mental health update — 10/22/26

✂️ Headspace issues layoffs following Sword Health acquisition (Ashleigh Hollowell, Behavioral Health Business) — 10/16/26
TL;DR: Two weeks after Sword Health’s reported $300M acquisition closed, the combined 1,203-person US workforce began planned post-transaction layoffs at director and senior levels, though Headspace’s C-suite leadership remains in place.

🏥 Creadev takes majority stake in French psychiatric care group Santé Basque (Nick Herbert, Investors in Healthcare) — 10/16/26
TL;DR: Creadev, the Mulliez family’s investment firm, acquired a majority stake in Bayonne-based Groupe Santé Basque Développement, which runs five psychiatric clinics covering eating disorders, addiction, bipolar disorders, and youth psychiatry, to accelerate growth across France and Europe.

🤖 Sword unveils Dawn 1, a frontier AI model purpose-built for mental health support (Sword Research) — 10/14/26
TL;DR: Sword introduced Dawn 1, a post-trained model powering its AI Care platform that outperforms frontier systems on multi-turn safety protocols, memory, and situational awareness, while cutting sycophantic tendencies and verbosity.

🧠 FDA clears Motivista (CT-155), first authorized treatment for negative symptoms of schizophrenia (Click Therapeutics) — 10/05/26
TL;DR: Click Therapeutics received FDA 510(k) clearance for Motivista, a prescription digital therapeutic that showed a 62% relative improvement over control in negative schizophrenia symptoms in the Phase III CONVOKE trial.